Unnamed: 0,title,date,stock,sentiment
1161002.0,20 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-06-10 07:35:00-04:00,SNSS,neutral
1161003.0,"H.C. Wainwright Reiterates Neutral on Sunesis Pharmaceuticals, Lowers Price Target to $0.5",2020-05-08 10:49:00-04:00,SNSS,negative
1161004.0,Sunesis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.,2020-05-08 08:17:00-04:00,SNSS,neutral
1161005.0,Sunesis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.,2020-05-07 17:31:00-04:00,SNSS,neutral
1161006.0,"Sunesis Pharmaceuticals Q1 EPS $(0.050) Beats $(0.070) Estimate, Sales $120.000K Miss $190.000K Estimate",2020-05-07 16:55:00-04:00,SNSS,negative
1161007.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,SNSS,negative
1161008.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,SNSS,neutral
1161009.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-01 07:42:00-04:00,SNSS,neutral
1161010.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,SNSS,positive
1161011.0,"Sunesis Pharmaceuticals trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak, the healthcare sector has been extremely volatile.",2020-03-13 10:35:00-04:00,SNSS,neutral
1161012.0,"Benzinga's Top Upgrades, Downgrades For March 11, 2020",2020-03-11 09:33:00-04:00,SNSS,positive
1161013.0,Sunesis Pharmaceuticals shares are trading lower after Wells Fargo downgraded the stock from Overweight to Equal-Weight and lowered the price target from $3 to $1 per share.,2020-03-11 08:14:00-04:00,SNSS,positive
1161014.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,SNSS,positive
1161015.0,"H.C. Wainwright Reiterates Neutral on Sunesis Pharmaceuticals, Raises Price Target to $1",2020-03-11 08:03:00-04:00,SNSS,neutral
1161016.0,"Wells Fargo Downgrades Sunesis Pharmaceuticals to Equal-Weight, Lowers Price Target to $1",2020-03-11 07:57:00-04:00,SNSS,positive
1161017.0,Sunesis Pharmaceuticals Q4 EPS $(0.05) Beats $(0.07) Estimate,2020-03-10 16:10:00-04:00,SNSS,neutral
1161018.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,SNSS,negative
1161019.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,SNSS,negative
1161020.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-19 08:10:00-05:00,SNSS,neutral
1161021.0,43 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-28 23:40:00-05:00,SNSS,neutral
1161022.0,20 Biotechnology Stocks Moving In Tuesday's After-Market Session,2020-01-21 23:35:00-05:00,SNSS,neutral
1161023.0,29 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-21 23:28:00-05:00,SNSS,neutral
1161024.0,"Sunesis Pharma 8-K Shows Co. Granted Second 180-Calendar Day Compliance Period, Or Until Jul. 6, 2020, To Demonstrate Compliance",2020-01-07 17:32:00-05:00,SNSS,positive
1161025.0,36 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-19 08:28:00-05:00,SNSS,neutral
1161026.0,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-18 08:11:00-05:00,SNSS,neutral
1161027.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,SNSS,neutral
1161028.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,SNSS,positive
1161029.0,"Sunesis Pharma 8-K Shows Co. Entered Deal To Terminate Certain License Deal With Sumitomo For Patents Related To Vosaroxin, Related Compounds; Co. Will Make 1-Time Payment Of $150K",2019-12-06 16:43:00-05:00,SNSS,positive
1161030.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,SNSS,positive
1161031.0,"Sunesis Pharma Reports Data From Ongoing Phase 1b/2 Trial Of Vecabrutinib In Patients With CLL, Other B-Cell Malignancies",2019-12-05 11:41:00-05:00,SNSS,neutral
1161032.0,Stocks That Hit 52-Week Lows On Thursday,2019-12-05 10:33:00-05:00,SNSS,negative
1161033.0,Sunesis Pharmaceuticals Q3 EPS $(0.06) Beats $(0.08) Estimate,2019-11-12 16:12:00-05:00,SNSS,neutral
1161034.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,SNSS,neutral
1161035.0,28 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-29 08:33:00-04:00,SNSS,neutral
1161036.0,Sunesis Pharmaceuticals Announces Presentation Of SNS-510 Pre-Clinical Data At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics,2019-10-16 17:02:00-04:00,SNSS,negative
1161037.0,Sunesis Pharmaceuticals Option Alert: Oct 18 $1 Calls Sweep (4) near the Ask: 879 @ $0.25 vs 2818 OI; Ref=$0.8399,2019-08-09 11:07:00-04:00,SNSS,positive
1161038.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,SNSS,neutral
1161039.0,Sunesis Pharmaceuticals Q2 EPS $(0.09) Beats $(0.10) Estimate,2019-08-07 16:43:00-04:00,SNSS,neutral
1161040.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,SNSS,neutral
1161041.0,55 Biggest Movers From Yesterday,2019-07-12 05:18:00-04:00,SNSS,neutral
1161042.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-07-11 12:50:00-04:00,SNSS,neutral
1161043.0,35 Stocks Moving In Thursday's Pre-Market Session,2019-07-11 08:21:00-04:00,SNSS,neutral
1161044.0,Sunesis Pharmaceuticals shares are trading lower after the company announced a public offering of common and preferred stock.,2019-07-11 07:23:00-04:00,SNSS,neutral
1161045.0,"The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug",2019-07-11 06:17:00-04:00,SNSS,neutral
1161046.0,"7 Stocks To Watch For July 11, 2019",2019-07-11 05:19:00-04:00,SNSS,neutral
1161047.0,Sunesis Prices 33.33M Share Common Stock Offering @$0.60/Share,2019-07-11 04:00:00-04:00,SNSS,positive
1161048.0,Sunesis Reports Common And Preferred Stock Offering; Size Not Disclosed,2019-07-10 16:10:00-04:00,SNSS,neutral
1161049.0,Sunesis Pharmaceuticals shares are trading lower after the company announced a public offering of common and preferred stock.,2019-07-10 16:05:00-04:00,SNSS,neutral
1161050.0,52 Biggest Movers From Yesterday,2019-07-09 04:59:00-04:00,SNSS,neutral
1161051.0,"A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019",2019-07-08 13:50:00-04:00,SNSS,neutral
1161052.0,36 Stocks Moving In Monday's Mid-Day Session,2019-07-08 12:50:00-04:00,SNSS,neutral
1161053.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, July 8, 2019",2019-07-08 10:28:00-04:00,SNSS,positive
1161054.0,"Sunesis Pharmaceuticals shares are trading higher after the company announced it has completed the safety evaluation period for the 200 mg cohort of the Phase 1b/2 trial of vecabrutinib; to date, the safety profile has had no drug-related adverse events.",2019-07-08 09:29:00-04:00,SNSS,positive
1161055.0,"The Daily Biotech Pulse:  Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA",2019-06-14 08:47:00-04:00,SNSS,neutral
1161056.0,Sunesis Pharmaceuticals Option Alert: Jun 21 $1 Calls Sweep (31) near the Ask: 1429 @ $0.151 vs 114 OI; Earnings 8/6 After Close [est] Ref=$0.663,2019-06-12 13:40:00-04:00,SNSS,positive
1161057.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-06-08 16:09:00-04:00,SNSS,neutral
1161058.0,Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.,2019-05-31 10:25:00-04:00,SNSS,negative
1161059.0,Sunesis Pharmaceuticals Q1 EPS $(0.1) Beats $(0.17) Estimate,2019-05-08 16:53:00-04:00,SNSS,neutral
1161060.0,Sunesis Pharmaceuticals Q4 EPS $(0.16) Beats $(0.21) Estimate,2019-03-07 16:19:00-05:00,SNSS,neutral
1161061.0,"Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO",2019-03-07 07:48:00-05:00,SNSS,negative
1161062.0,52 Biggest Movers From Friday,2019-01-22 05:08:00-05:00,SNSS,neutral
1161063.0,36 Stocks Moving In Friday's Mid-Day Session,2019-01-18 12:30:00-05:00,SNSS,neutral
1161064.0,Sunesis Pharmaceuticals shares are trading lower after the company announced a 23 million share offering at $0.50 per share.,2019-01-18 10:33:00-05:00,SNSS,positive
1161065.0,40 Stocks Moving In Friday's Pre-Market Session,2019-01-18 08:07:00-05:00,SNSS,neutral
1161066.0,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",2019-01-18 07:49:00-05:00,SNSS,neutral
1161067.0,"10 Stocks To Watch For January 18, 2019",2019-01-18 04:43:00-05:00,SNSS,neutral
1161068.0,Sunesis Pharmaceuticals Prices 23M Share Offering @$0.50/Share,2019-01-18 03:30:00-05:00,SNSS,positive
1161069.0,"Sunesis Pharma Announces Proposed Common Stock and Preferred Stock Offer, Size Not Disclosed",2019-01-17 16:11:00-05:00,SNSS,neutral
1161070.0,Penny stock Sunesis Pharma shares up 27% on 3x normal daily volume despite a lack of news. Shares broke above the $0.60 resistance level at Friday morning's open.,2019-01-11 14:50:00-05:00,SNSS,positive
1161071.0,Sunesis Pharmaceuticals Announces Advancement Into 100mg Cohort Of Phase 1b/2 Trial Of Vecabrutinib In Patients With CLL And Other B-Cell Malignancies,2019-01-02 07:12:00-05:00,SNSS,neutral
1161072.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,SNSS,neutral
1161073.0,"H.C. Wainwright Initiates Coverage On Sunesis Pharmaceuticals with Neutral Rating, Announces $0.50 Price Target",2018-12-20 07:46:00-05:00,SNSS,neutral
1161074.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,SNSS,positive
1161075.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,SNSS,positive
1161076.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,SNSS,neutral
1161077.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,SNSS,neutral
1161078.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:21:00-05:00,SNSS,negative
1161079.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,SNSS,neutral
1161080.0,Sunesis Pharmaceuticals Announces Presentation of Encouraging Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH 2018,2018-12-02 19:03:00-05:00,SNSS,positive
1161081.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,SNSS,neutral
1161082.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,SNSS,negative
1161083.0,"The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings",2018-11-28 07:46:00-05:00,SNSS,neutral
1161084.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,SNSS,negative
1161085.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,SNSS,negative
1161086.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018",2018-11-23 09:09:00-05:00,SNSS,negative
1161087.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018",2018-11-20 09:12:00-05:00,SNSS,negative
1161088.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,SNSS,positive
1161089.0,"Sunesis Pharmaceuticals, Inc. Q3 EPS $(0.18) Beats $(0.22) Estimate",2018-11-05 16:36:00-05:00,SNSS,neutral
1161090.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,SNSS,neutral
1161091.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,SNSS,negative
1161092.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,SNSS,negative
1161093.0,Sunesis Pharmaceuticals Q2 EPS $(0.20) Beats $(0.24) Estimate,2018-08-07 17:19:00-04:00,SNSS,neutral
1161094.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,SNSS,negative
1161095.0,"UPDATE: Sunesis Pharma Announces Aspire Capital Made Initial Investment Via Purchase of $500K Worth Of Common Shares at $2.19/Share, Has Committed To Purchasing An Additional $15M",2018-06-25 16:12:00-04:00,SNSS,positive
1161096.0,Sunesis Pharma Enters Purchase Agreement With Aspire Capital For $15.5M Common Stock,2018-06-25 16:11:00-04:00,SNSS,positive
1161097.0,45 Biggest Movers From Yesterday,2018-06-08 04:07:00-04:00,SNSS,neutral
1161098.0,"Sunesis Pharmaceuticals Q1 EPS $(0.21) Beats $(0.27) Estimate, Sales $237K Beat $200K Estimate",2018-05-08 16:01:00-04:00,SNSS,neutral
1161099.0,42 Biggest Movers From Yesterday,2018-03-15 05:18:00-04:00,SNSS,neutral
1161100.0,"Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference, Cancellation Due to Travel Changes Caused by Inclement Weather",2018-03-13 07:05:00-04:00,SNSS,positive
1161101.0,Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference Due to Travel Changes Caused by Weather,2018-03-13 07:02:00-04:00,SNSS,positive
1161102.0,44 Biggest Movers From Friday,2018-03-12 04:59:00-04:00,SNSS,neutral
1161103.0,Mid-Afternoon Market Update: Crude Oil Up Over 3%; PDL BioPharma Shares Spike Higher,2018-03-09 14:32:00-05:00,SNSS,negative
1161104.0,Sunesis Pharma Down 41% On Extended Timeline For Vecabrutinib Dose-Escalation Study,2018-03-09 13:21:00-05:00,SNSS,neutral
1161105.0,36 Stocks Moving In Friday's Mid-Day Session,2018-03-09 12:41:00-05:00,SNSS,neutral
1161106.0,Mid-Day Market Update: Dow Rises Over 250 Points; AutoWeb Shares Plunge,2018-03-09 12:04:00-05:00,SNSS,positive
1161107.0,Mid-Morning Market Update: Markets Open Higher; Finisar Earnings Miss Views,2018-03-09 10:13:00-05:00,SNSS,negative
1161108.0,Sunesis Pharma Reports Q4 EPS $(0.21) vs $(0.29) Est.,2018-03-08 16:27:00-05:00,SNSS,neutral
1161109.0,Sunesis Pharmaceuticals Q4 Earnings Preview,2018-03-08 10:25:00-05:00,SNSS,neutral
1161110.0,"Sunesis Pharma 13G Filing From Boxer Capital Shows Raised Stake From 1.325M Shares At End Of Last Qtr. To 2.125M Shares, Or 6.2% Stake",2018-03-05 17:27:00-05:00,SNSS,positive
1161111.0,46 Biggest Movers From Yesterday,2018-02-01 04:46:00-05:00,SNSS,neutral
1161112.0,36 Biggest Movers From Yesterday,2018-01-05 05:48:00-05:00,SNSS,neutral
1161113.0,Mid-Day Market Update: Buckle Drops After December Sales Results; ChemoCentryx Shares Spike Higher,2018-01-04 12:41:00-05:00,SNSS,positive
1161114.0,33 Stocks Moving In Thursday's Mid-Day Session,2018-01-04 12:25:00-05:00,SNSS,neutral
1161115.0,42 Biggest Movers From Yesterday,2017-12-12 05:56:00-05:00,SNSS,neutral
1161116.0,Sunesis Pharmaceuticals Spikes to High of $3.57 on Volume,2017-12-11 14:51:00-05:00,SNSS,neutral
1161117.0,30 Stocks Moving In Monday's Mid-Day Session,2017-12-11 12:07:00-05:00,SNSS,neutral
1161118.0,"Benzinga's Top Upgrades, Downgrades For December 11, 2017",2017-12-11 09:31:00-05:00,SNSS,positive
1161119.0,Wells Fargo Upgrades Sunesis Pharmaceuticals to Outperform,2017-12-11 07:51:00-05:00,SNSS,positive
1161120.0,"Benzinga's Top Upgrades, Downgrades For December 5, 2017",2017-12-05 09:32:00-05:00,SNSS,positive
1161121.0,Wells Fargo Downgrades Sunesis Pharmaceuticals to Market Perform,2017-12-05 07:40:00-05:00,SNSS,positive
1161122.0,Sunesis Pharmaceuticals Says it Will Provide a Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017,2017-12-05 07:08:00-05:00,SNSS,negative
1161123.0,"Sunesis Pharmaceuticals CEO Daniel Swisher CEO Resigns Effective End of 2017, Will Remain As Strategic Advisor, Dayton Misfeldt Named Interim CEI Effective Jan. 2018",2017-12-04 16:06:00-05:00,SNSS,positive
1161124.0,Sunesis Pharma Names William Quinn CFO,2017-11-30 07:08:00-05:00,SNSS,neutral
1161125.0,40 Biggest Movers From Yesterday,2017-11-22 05:03:00-05:00,SNSS,neutral
1161126.0,40 Stocks Moving In Tuesday's Mid-Day Session,2017-11-21 12:42:00-05:00,SNSS,neutral
1161127.0,"Benzinga's Top Upgrades, Downgrades For November 21, 2017",2017-11-21 08:56:00-05:00,SNSS,positive
1161128.0,Oppenheimer Initiates Coverage On Sunesis Pharmaceuticals with Outperform Rating,2017-11-21 08:04:00-05:00,SNSS,neutral
1161129.0,"STAT's Adam Feurstein Tweets: 'There's an analyst named Hartaj Singh at Oppenheimer who just initiated on $CLSN and $SNSS w/ outperform ratings, $9 and $7 PTs, respectively. Poor guy. FHL.'",2017-11-20 16:17:00-05:00,SNSS,negative
1161130.0,"Sunesis Pharmaceuticals 10%+ Owner UBS Oncology Impact Fund L.P. Buys 81,500 @ Avg Price: $2.77 -Form 4",2017-11-07 04:10:00-05:00,SNSS,neutral
1161131.0,"Sunesis Pharma Reports Q3 EPS $(0.43) vs. $(0.37) Est., No Sales",2017-11-02 09:50:00-04:00,SNSS,negative
1161132.0,46 Biggest Movers From Yesterday,2017-11-01 05:27:00-04:00,SNSS,neutral
1161133.0,"Sunesis Pharmaceuticals Director Dayton Misfeldt Buys 600,000 @ Avg Price: $1.33 -Form4",2017-10-31 03:50:00-04:00,SNSS,neutral
1161134.0,"Sunesis Pharma Reports Offering Of Common Stock, Series D Convertible Preferred Shares, Warrants, No Size Disclosed",2017-10-24 16:10:00-04:00,SNSS,neutral
1161135.0,Sunesis Pharmaceuticals Reports Q2 EPS $(0.41) vs $(0.59) Est.,2017-07-27 09:01:00-04:00,SNSS,neutral
1161136.0,"Sunesis Pharma Reports First Patient Dosed In Phase 1b/2 Study Evaluating SNS-062 In Adults With Chronic Lymphocytic Leukemia, Other B-Cell Malignancies",2017-07-18 16:10:00-04:00,SNSS,neutral
1161137.0,13G Filing From Balyasny Asset Mgmt On Sunesis Pharma Shows 9.32% Stake,2017-07-05 14:20:00-04:00,SNSS,positive
1161138.0,"UPDATE: Sunesis Says 32 Out Of 35 Patients Completed Greater Than Or Equal To 1 Cycle, Were Evaluable For Response",2017-06-23 07:08:00-04:00,SNSS,positive
1161139.0,Sunesis Pharma Offers Updated Results From Phase 1/Cohort Expansion Trial Of Vosaroxin Plus Azacitidine In Patients With MDS: Showed Encouraging Response Rates,2017-06-23 07:08:00-04:00,SNSS,positive
1161140.0,"Sunesis Pharma Q1 EPS $(0.47) vs $(0.17) Est, Sales $669K vs $630K Est",2017-05-08 07:12:00-04:00,SNSS,neutral
1161141.0,18 Biggest Mid-Day Losers For Tuesday,2017-05-02 13:10:00-04:00,SNSS,negative
1161142.0,Mid-Morning Market Update: Markets Mostly Flat; Pfizer Profit Beats Views,2017-05-02 10:10:00-04:00,SNSS,positive
1161143.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-05-02 08:05:00-04:00,SNSS,neutral
1161144.0,"Adam F Tweets: I've spoken to few buysiders own $SNSS for SNS-062, early, different BTK inhibitor. ""Thrilled"" to see vosa off the books, one just told me.",2017-05-01 16:59:00-04:00,SNSS,negative
1161145.0,Sunesis Pharma Reports Withdrawal of European MAA for Vosaroxin as Treatment for Relapsed/Refractory AML,2017-05-01 16:36:00-04:00,SNSS,positive
1161146.0,8-K from Sunesis Pharma Shows CFO Eric Bjerkholt to Resign; Co. to Initiate Search for Replacement Candidate,2017-04-12 17:11:00-04:00,SNSS,negative
1161147.0,Sunesis Pharma Reports Submission of Responses to EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin,2017-03-22 07:10:00-04:00,SNSS,positive
1161148.0,Sunesis Pharmaceuticals Reports FDA Review Of INDA For SNS-062 Complete; Says Vosaroxin Outstanding Issues Received And Will Go Before Scientific Advisory Group In April Prior To CHMP Opinion,2017-01-23 07:01:00-05:00,SNSS,positive
1161149.0,"Sunesis Pharmaceuticals Reports Q3 EPS $(0.62) vs. Est. $(0.71), Rev. $610K vs. Est. $600K",2016-11-03 07:16:00-04:00,SNSS,neutral
1161150.0,"Sunesis Announces Pricing of $25 Million Offering of Securities, 4.93M Shares At $3.85/Share",2016-10-19 09:03:00-04:00,SNSS,positive
1161151.0,"Sunesis Reports Offering of Common Stock, Series C Convertible Preferred Shares, No Amount Disclosed",2016-10-18 16:03:00-04:00,SNSS,neutral
1161152.0,UPDATE: Sunesis Says Expects to Receive EMA Day 180 List of Outstanding Issues Before Year End,2016-10-13 16:08:00-04:00,SNSS,positive
1161153.0,Sunesis Reports Submission of Response to EMA Day 120 List of Questions for MAA for Vosaroxin,2016-10-13 16:07:00-04:00,SNSS,neutral
1161154.0,"Sunesis Phase 1A Study of SNS-062 Showed Favorable Safety, Pharmacokinetic and Pharmacodynamic Results",2016-09-12 06:06:00-04:00,SNSS,positive
1161155.0,Sunesis Upgraded To Outperform At Wells Fargo,2016-07-29 08:04:00-04:00,SNSS,positive
1161156.0,"Sunesis Pharmaceuticals Reports Q2 EPS $(0.12) vs. Est. $(0.10), Rev. $610K vs. Est. $1M",2016-07-29 07:05:00-04:00,SNSS,neutral
1161157.0,Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the EHA,2016-05-19 07:29:00-04:00,SNSS,neutral
1161158.0,Sunesis Pharmaceuticals Reports Q1 EPS $(0.12) vs. Est. $(0.12),2016-05-05 07:18:00-04:00,SNSS,neutral
1161159.0,Sunesis Pharma Reports First Patient Treated in Phase 2 VITAL Study of Vosaroxin in Combo with Infusional Cytarabine in Patients with Previously Untreated AML,2016-03-24 07:02:00-04:00,SNSS,positive
1161160.0,Sunesis Pharma Reports First Dosing in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062,2016-03-23 07:05:00-04:00,SNSS,positive
1161161.0,Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062,2016-03-23 07:03:00-04:00,SNSS,positive
1161162.0,Sunesis Pharmaceuticals Reports Q4 EPS $(0.15) vs. Est. $(0.14),2016-03-10 07:05:00-05:00,SNSS,neutral
1161163.0,Growth Equity Opportunities Fund Reports 9% Stake In Sunesis Pharmaceuticals 13D Filing,2016-01-07 16:25:00-05:00,SNSS,positive
1161164.0,Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals to Speculative Buy,2016-01-05 08:16:00-05:00,SNSS,positive
1161165.0,Sunesis Pharma Reports EMA Validation of MAA for Vosaroxin in AML,2016-01-04 07:02:00-05:00,SNSS,positive
1161166.0,Amended 13D Filing from Bay City Capital on Sunesis Pharma Shows 8.52% Stake,2015-12-22 17:00:00-05:00,SNSS,neutral
1161167.0,"Director Misfeldt Buys 1,750,000 Shares of Sunesis Pharmaceuticals @$0.84/Share -Form 4",2015-12-22 04:18:00-05:00,SNSS,positive
1161168.0,Sunesis Prices 9.561M Shares At $0.84/Share,2015-12-16 08:20:00-05:00,SNSS,positive
1161169.0,Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe,2015-12-08 07:02:00-05:00,SNSS,neutral
1161170.0,Sunesis Pharmaceuticals Announces Positive Results Regarding ongoing Phase 1b/2 University of Texas MD Anderson cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients,2015-12-07 07:01:00-05:00,SNSS,negative
1161171.0,Sunesis Pharmaceuticals Announces Presentation of Results Phase 1 Trial of Vosaroxin + Azacitidine at #ASH2015,2015-12-06 08:41:00-05:00,SNSS,neutral
1161172.0,"Sunesis Reports Partnership with Clinigen Group Related to Initiation of Compassionate Use Program for Patients with Relapsed, Refractory AML",2015-12-03 07:08:00-05:00,SNSS,positive
1161173.0,"Sunesis Pharma Initiates IU Pilot Study Of Vosaroxin, Cytarabine Treatment In ~17 Patients 60 Years or Older With Untreated AML",2015-12-01 07:03:00-05:00,SNSS,positive
1161174.0,Sunesis Pharma Announces European Patent For Vosaroxin Combination Use,2015-11-30 07:04:00-05:00,SNSS,neutral
1161175.0,Sunesis Pharmaceuticals Reports Q3 Loss $0.09 Vs Est Loss $0.15,2015-11-05 07:09:00-05:00,SNSS,negative
1161176.0,Sunesis Pharma Reports Presentation of Responder Survival Analysis from Phase 3 VALOR Trial at CFS,2015-11-04 18:02:00-05:00,SNSS,neutral
1161177.0,Sunesis Announces Anticipated Submission of European Marketing Authorization Application for Vosaroxin in AML Before Year End,2015-10-07 16:05:00-04:00,SNSS,positive
1161178.0,"Sunesis Pharmaceuticals CEO Swisher Jr Buys 25,000 Shares @$1.02/Share -Form 4",2015-07-29 04:16:00-04:00,SNSS,positive
1161179.0,"Biotech Stocks Falling Broadly, Here's Why And How Much",2015-07-26 21:57:00-04:00,SNSS,negative
1161180.0,"Market Update: Friday's Mid-Day Market Movers: Amazon Shocks The Markets; Anthem, Cigna, StanCorp, Pandora",2015-07-24 13:28:00-04:00,SNSS,negative
1161181.0,"Worst Performing Industries For July 24, 2015",2015-07-24 11:30:00-04:00,SNSS,negative
1161182.0,Morning Market Losers,2015-07-24 09:55:00-04:00,SNSS,negative
1161183.0,Benzinga's Top Downgrades,2015-07-24 09:29:00-04:00,SNSS,positive
1161184.0,"Roth's Pantginis Downgrades Sunesis, Price Target Smashed To $1.00 On 'Many Outstanding Questions'",2015-07-24 09:23:00-04:00,SNSS,positive
1161185.0,Cowen & Company Downgrades Sunesis Pharmaceuticals to Market Perform,2015-07-24 07:41:00-04:00,SNSS,neutral
1161186.0,Sunesis Pharma Shares Plunge 60%+ Following Release Suggesting Co. Has Been Informed FDA Will Not Support Recent Vosaroxin Filing,2015-07-23 17:06:00-04:00,SNSS,neutral
1161187.0,Sunesis Pharmaceuticals Reports Regulatory Update,2015-07-23 16:12:00-04:00,SNSS,neutral
1161188.0,Option Alert: Sunesis Aug $4 Call Sweep; 2000 Contracts at Ask @$0.15,2015-07-01 14:26:00-04:00,SNSS,positive
1161189.0,Option Alert: Sunesis Aug $4 Call Sweep; 1575 Contracts above Ask @$0.34,2015-06-30 15:58:00-04:00,SNSS,positive
1161190.0,Option Alert: Sunesis Pharmaceuticals Aug $4 Call; 2141 Contracts Traded vs 3 OI; Now $2.96,2015-06-30 15:12:00-04:00,SNSS,positive
1161191.0,"Roth Capital's Pantginis Says 'Cautious Optimism Grows' on Sunesis Pharma, Warns 'AML Still Dire Need,' Raises Target from $4 to $5.50",2015-06-15 07:44:00-04:00,SNSS,positive
1161192.0,"Roth Capital Maintains Buy on Sunesis Pharmaceuticals, Raises PT to $5.50",2015-06-15 07:34:00-04:00,SNSS,neutral
1161193.0,Morning Market Gainers,2015-06-12 09:49:00-04:00,SNSS,neutral
1161194.0,Sunesis Pharma Offers New Data from VALOR Trial for Vosaroxin in Oilder Patients with Acute Myeloid Leukemia,2015-06-12 07:01:00-04:00,SNSS,neutral
1161195.0,Sunesis Pharmaceuticals Presentats VALOR Trial Subgroup Analysis at ASCO,2015-05-31 09:35:00-04:00,SNSS,neutral
1161196.0,Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association,2015-05-21 08:13:00-04:00,SNSS,neutral
1161197.0,Sunesis Pharma Q4 EPS -$0.02 vs -$0.20 est,2015-03-12 07:04:00-04:00,SNSS,neutral
1161198.0,"Option Alert: Sunesis Pharmaceuticals Feb $3 Call; 6,900 Contract Trade at Bid @$.30; Currently $2.79",2015-01-12 09:57:00-05:00,SNSS,positive
1161199.0,"Option Alert: Sunesis Pharmaceuticals Feb $3 Call, 1,037 Contract Trade at Ask @$0.45; Currently $2.69",2015-01-08 10:55:00-05:00,SNSS,positive
1161200.0,"BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will Be Breakeven By 2017'",2015-01-05 19:19:00-05:00,SNSS,neutral
1161201.0,"BTIG Research Initiates Coverage on Sunesis Pharmaceuticals at Buy, Announces $5.50 PT",2015-01-05 17:27:00-05:00,SNSS,neutral
1161202.0,"Roth Capital Upgrades Sunesis Pharmaceuticals, Inc. to Buy, Raises PT to $4.30",2014-12-15 05:14:00-05:00,SNSS,neutral
1161203.0,Sunesis Pharmaceuticals Shares Rise 13% Premarket Following Cantor Fitzgerald Upgrade to Buy,2014-12-10 07:46:00-05:00,SNSS,positive
1161204.0,"Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals, Inc. to Buy",2014-12-10 06:43:00-05:00,SNSS,neutral
1161205.0,Sunesis Announces Presentation Of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS at ASH Annual Meeting,2014-12-08 13:32:00-05:00,SNSS,positive
1161206.0,Morning Market Losers,2014-12-08 09:53:00-05:00,SNSS,negative
1161207.0,Sunesis Pharmaceuticals to Presentat Results from Phase 3 VALOR Trial at ASH Annual Meeting,2014-12-07 16:18:00-05:00,SNSS,neutral
1161208.0,"Option Alert: Sunesis Pharmaceuticals Dec $2 Call; 1,000 Contract Trade at Ask @$.50; Currently $2.22",2014-11-25 11:14:00-05:00,SNSS,positive
1161209.0,UPDATE: Sunesis Reports Schedule C Had Most Favorably Safety/Efficacy Balance,2014-11-24 07:24:00-05:00,SNSS,positive
1161210.0,Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology,2014-11-24 07:06:00-05:00,SNSS,neutral
1161211.0,Sunesis Announces Publication Of Vosaroxin Phase 1b/2 AML Trial Results In Haematologica,2014-11-19 07:01:00-05:00,SNSS,positive
1161212.0,"Option Alert: Sunesis Dec $2.5 Call; 2,027 Contract Trade at Ask @$.30; Currently $2.31",2014-11-17 11:45:00-05:00,SNSS,positive
1161213.0,Sunesis Pharmaceuticals Announces Late-Breaking Presentation Of Phase 3 VALOR Trial At ASH Annual Meeting,2014-11-17 09:06:00-05:00,SNSS,neutral
1161214.0,"Sunesis Pharmaceuticals, Inc. Reports Q3 EPS of $(0.25) vs $(0.17) Est",2014-11-10 07:04:00-05:00,SNSS,neutral
1161215.0,"Earnings Scheduled For November 10, 2014",2014-11-10 05:36:00-05:00,SNSS,neutral
1161216.0,"Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth",2014-10-07 16:19:00-04:00,SNSS,negative
1161217.0,"Roth Capital Downgrades Sunesis Pharmaceuticals, Inc. to Buy, Lowers PT to $15.00",2014-10-07 05:55:00-04:00,SNSS,negative
1161218.0,"RBC Capital Downgrades Sunesis Pharmaceuticals, Inc. to Sector Perform, Lowers PT to $3.00",2014-10-06 15:31:00-04:00,SNSS,negative
1161219.0,"U.S. Stocks Turn Red; CareFusion Shares Surge On Announcement Of Acquisition By Becton, Dickinson",2014-10-06 14:00:00-04:00,SNSS,positive
1161220.0,"Wedbush Maintains Neutral on Sunesis Pharmaceuticals, Inc., Lowers PT to $2.00",2014-10-06 12:58:00-04:00,SNSS,negative
1161221.0,Markets Open Higher; Hewlett-Packard Plans To Split Into Two Companies,2014-10-06 10:58:00-04:00,SNSS,neutral
1161222.0,Stocks Hitting 52-Week Lows,2014-10-06 10:20:00-04:00,SNSS,negative
1161223.0,Morning Market Losers ,2014-10-06 09:47:00-04:00,SNSS,negative
1161224.0,Benzinga's Top #PreMarket Losers,2014-10-06 08:08:00-04:00,SNSS,negative
1161225.0,Sunesis Shares Fall 64% Premarket as Pivotal Phase 3 VALOR Trial of Acute Myeloid Leukemia Treatment does Not Meet Primary Endpoint,2014-10-06 07:40:00-04:00,SNSS,positive
1161226.0,Sunesis Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine  Does Not Reach Primary Endpoint,2014-10-06 06:48:00-04:00,SNSS,neutral
1161227.0,Shares of Sunesis Pharmaceuticals Move Lower; May be Attributed to Adam F/Street.com Article ,2014-09-02 10:35:00-04:00,SNSS,neutral
1161228.0,"Option Alert: Sunesis Pharma Oct $14 Call; 1,022 Contracts Traded vs 529 OI; Currently $7.45",2014-08-29 13:25:00-04:00,SNSS,positive
1161229.0,Morning Market Losers ,2014-08-29 09:52:00-04:00,SNSS,negative
1161230.0,Benzinga's Top Downgrades,2014-08-29 09:15:00-04:00,SNSS,positive
1161231.0,"Wedbush Downgrades Sunesis Pharmaceuticals To Neutral, Shares Drop",2014-08-29 08:31:00-04:00,SNSS,neutral
1161232.0,"Wedbush Downgrades Sunesis Pharmaceuticals, Inc. to Neutral",2014-08-29 06:55:00-04:00,SNSS,neutral
1161233.0,UBS Says Sunesis Leukemia Pivotal Trial Success 'Likely',2014-08-27 16:05:00-04:00,SNSS,positive
1161234.0,"Shares of Sunesis Pharma Spiked Over $8 Level During Last Hour, Traders Attributing Move to CNBC Mention of Comments from UBS Analyst in Early-Morning Research Note",2014-08-27 15:22:00-04:00,SNSS,positive
1161235.0,"Sunesis Pharmaceuticals, Inc. Reports Q2 EPS of $(0.20) vs $(0.17) Est; Revenue of $1.99M vs $1.21M Est",2014-08-05 07:05:00-04:00,SNSS,neutral
1161236.0,Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo For AML,2014-07-09 07:04:00-04:00,SNSS,positive
1161237.0,Events Scheduled for Week of Jun. 16th to Jun. 20th,2014-06-17 10:48:00-04:00,SNSS,neutral
1161238.0,"UBS Initiates Coverage on Sunesis Pharmaceuticals, Inc. at Buy, Announces $14.00 PT",2014-06-11 16:33:00-04:00,SNSS,neutral
1161239.0,Sunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASCO 2014 Annual Meeting ,2014-06-02 07:02:00-04:00,SNSS,positive
1161240.0,Sunesis Announces Data of Ongoing Vosaroxin Study at ASCO,2014-04-22 07:09:00-04:00,SNSS,neutral
1161241.0,Mid-Morning Market Update: Markets Drop; Family Dollar Plans To Close 370 Stores,2014-04-10 10:27:00-04:00,SNSS,negative
1161242.0,"Sunesis Reports Presentation of Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML, High-Risk MDS",2014-04-08 08:03:00-04:00,SNSS,positive
1161243.0,Sunesis MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014 ,2014-04-02 07:06:00-04:00,SNSS,positive
1161244.0,"Sunesis Pharmaceuticals, Inc. Reports Q4 EPS of $(0.15) vs $(0.20) Est",2014-03-06 07:04:00-05:00,SNSS,neutral
1161245.0,"Leerink Swann Boosts Target on Sunesis Pharma from $14 to $17, Maintains Outerpform",2014-03-05 15:08:00-05:00,SNSS,positive
1161246.0,"Sunesis Prices $43M Offering of Stocks, Warrants, Expecting Total Gross Proceeds $138.3M",2014-02-27 08:34:00-05:00,SNSS,negative
1161247.0,Sunesis Announces Proposed Public Offering,2014-02-26 16:16:00-05:00,SNSS,neutral
1161248.0,Sunesis Names Joseph I. DePinto Chief Commercial Officer,2014-02-10 07:07:00-05:00,SNSS,neutral
1161249.0,Hearing Cowen Positive on Sunesis Pharmaceuticals,2014-02-07 07:44:00-05:00,SNSS,positive
1161250.0,Sunesis Pharmaceuticals Announces Global Licenses for Two Kinase Inhibitor Programs ,2014-01-09 07:06:00-05:00,SNSS,negative
1161251.0,Sunesis Pharmaceuticals Initiates Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS ,2013-12-10 07:04:00-05:00,SNSS,neutral
1161252.0,"Sunesis Pharmaceuticals, Inc. Reports Q3 EPS of $(0.16) vs $(0.20) Est; Revenue of $1.99M vs $1.44M Est",2013-11-12 07:21:00-05:00,SNSS,neutral
1161253.0,Sunesis Pharmaceuticals Announces Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in Myelodysplastic Syndrome ,2013-10-28 07:07:00-04:00,SNSS,neutral
1161254.0,Benzinga's Top Initiations,2013-07-31 09:00:00-04:00,SNSS,positive
1161255.0,"Credit Suisse Initiates Coverage on Sunesis Pharmaceuticals, Inc. at Buy, Announces $25.00 PT",2013-07-31 08:57:00-04:00,SNSS,positive
1161256.0,"Sunesis Pharmaceuticals, Inc. Reports Q2 EPS of $(0.18) vs $(0.21) Est; Revenue of $1.99M vs $1.22M Est",2013-07-29 16:14:00-04:00,SNSS,neutral
1161257.0,Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial With no Change to Study Conduct,2013-06-13 07:09:00-04:00,SNSS,positive
1161258.0,"Sunesis Pharmaceuticals, Inc. Reports Q1 EPS of $(0.23) vs $(0.20) Est",2013-05-09 07:56:00-04:00,SNSS,neutral
1161259.0,Sunesis Pharma Files $150M Mixed Securities Shelf,2013-04-10 17:34:00-04:00,SNSS,positive
1161260.0,"Sunesis Pharmaceuticals, Inc. Reports Q4 EPS of $(0.20) vs $(0.19) Est; Revenue of $1.99M vs $320.0K Est",2013-03-13 07:07:00-04:00,SNSS,neutral
1161261.0,"Earnings Scheduled For March 13, 2013",2013-03-13 04:21:00-04:00,SNSS,neutral
1161262.0,Sunesis Pharmaceuticals Spikes Lower,2013-02-07 14:53:00-05:00,SNSS,negative
1161263.0,UPDATE: Credit Suisse Initiates Sunesis Pharmaceuticals at Outperform Ahead of Phase II Data  ,2013-01-15 12:31:00-05:00,SNSS,positive
1161264.0,"Credit Suisse Initiates Coverage on Sunesis Pharmaceuticals, Inc. at Outperform, Announces $7.00 PT",2013-01-15 08:33:00-05:00,SNSS,positive
1161265.0,"From Earlier: Wells Fargo Initiates Coverage on Sunesis Pharmaceuticals, Inc. at Outperform",2012-12-20 10:28:00-05:00,SNSS,positive
1161266.0,"Wedbush Securities Maintains Sunesis Pharmaceuticals at Outperform, Raises PT from $7 to $10",2012-10-05 11:12:00-04:00,SNSS,positive
1161267.0,Sunesis Pharmaceuticals Spokesperson Says No News to Account for Spikedown,2012-10-02 15:28:00-04:00,SNSS,negative
1161268.0,Sunesis Pharmaceuticals Spikes Lower,2012-10-02 15:13:00-04:00,SNSS,negative
1161269.0,Sunesis Pharmaceuticals Announces Closing of $40 Million in Previously Announced Royalty and Debt Financings,2012-09-20 07:04:00-04:00,SNSS,negative
1161270.0,"Wedbush Securities Maintains Sunesis Pharmaceuticals at Outperform, Raises PT from $4 to $7",2012-09-11 12:43:00-04:00,SNSS,positive
1161271.0,Stocks Hitting 52-Week Highs,2012-09-11 10:03:00-04:00,SNSS,neutral
1161272.0,Morning Market Movers,2012-09-11 09:48:00-04:00,SNSS,neutral
1161273.0,UPDATE: Sunesis Pharmaceuticals Rises 46% Pre-Market on Increase in Patient Sample Size in Acute Myeloid Leukemia Trial,2012-09-11 08:25:00-04:00,SNSS,positive
1161274.0,From Earlier: Sunesis Pharmaceuticals to Implement One-Time Sample Size Increase to Phase 3 VALOR Trial in AML,2012-09-11 08:21:00-04:00,SNSS,positive
1161275.0,Sunesis Pharmaceuticals Reports Q2 EPS $-0.20 vs $-0.20 Est,2012-08-09 07:44:00-04:00,SNSS,neutral
1161276.0,"Cantor Fitzgerald Reiterates Buy Rating, $6 PT for Sunesis Pharmaceuticals",2012-06-15 10:42:00-04:00,SNSS,neutral
1161277.0,"Cantor Fitzgerald Initiates Coverage on Sunesis Pharmaceuticals with Buy Rating, $6 PT",2012-04-13 10:41:00-04:00,SNSS,neutral
1161278.0,"Cantor Fitzgerald Initiates Coverage on Sunesis Pharmaceuticals at Buy, Announces PT of $6",2012-04-13 06:59:00-04:00,SNSS,neutral
1161279.0,"Benzinga's Microcap Movers for Friday March 30, 2012",2012-04-01 09:15:00-04:00,SNSS,neutral
1161280.0,Sunesis and Royalty Pharma Announce $25M Vosaroxin Royalty Agreement  ,2012-03-29 16:24:00-04:00,SNSS,positive
1161281.0,"Canaccord Initiates Coverage on Sunesis Pharmaceuticals at Buy, Announces PT of $4",2012-03-06 08:15:00-05:00,SNSS,neutral
1161282.0,"Benzinga's Microcap Movers for Monday March 5, 2012",2012-03-05 22:18:00-05:00,SNSS,neutral
1161283.0,A Peek Into The Market Before The Trading Starts,2012-02-14 07:27:00-05:00,SNSS,neutral
1161284.0,Sunesis Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Covering Vosaroxin Compositions ,2012-02-14 07:06:00-05:00,SNSS,neutral
1161285.0,"Small Biotechnology Stocks Roar, Profit Now",2012-01-26 14:03:00-05:00,SNSS,positive
1161286.0,Sunesis Announces Participation in Cardiff University Sponsored Phase 2/3 Trial Evaluating Vosaroxin in Newly Diagnosed Elderly AML and High-Risk MDS Patients  ,2011-12-12 07:02:00-05:00,SNSS,positive
1161287.0,Sunesis Secures $25 Million Tranched Loan Facility ,2011-10-19 16:22:00-04:00,SNSS,positive
1161288.0,Hearing Wedbush Initiates Sunesis Pharmaceuticals with $4 PT,2011-10-07 12:33:00-04:00,SNSS,neutral
1161289.0,MLV Initiates Coverage of Sunesis Pharmaceuticals with a Buy Rating,2011-09-29 10:00:00-04:00,SNSS,neutral
1161290.0,MLV Initiates Sunesis Pharmaceuticals with Buy; $3.50 PT,2011-09-29 09:52:00-04:00,SNSS,neutral
1161291.0,Sunesis Announces Initiation of Phase 1 Study of MLN2480 in Advanced Solid Tumors  ,2011-09-26 07:05:00-04:00,SNSS,positive
1161292.0,Sunesis Announces Initiation of Phase 1 Study of MLN2480 in Advanced Solid Tumors  ,2011-09-26 07:05:00-04:00,SNSS,positive
1161293.0,NASDAQ Stocks Hitting 52-Week Lows,2011-08-08 10:11:00-04:00,SNSS,negative
1161294.0,Sunesis Pharmaceuticals Issued U.S. Patent Covering Vosaroxin Use to Treat Leukemia  ,2011-08-03 07:10:00-04:00,SNSS,positive
1161295.0,Sunesis Announces Publication of Phase 1b Data of Vosaroxin in Relapsed or Refractory Acute Leukemia  ,2011-07-20 07:36:00-04:00,SNSS,neutral
1161296.0,Top Percentage Gainers and Losers as of 2pm 06/07/11,2011-06-07 14:27:00-04:00,SNSS,negative
1161297.0,Top Percentage Gainers and Losers as of 12pm 06/07/11,2011-06-07 12:00:00-04:00,SNSS,negative
1161298.0,Sunesis Announces Presentation of Adaptive Study Design for Vosaroxin Phase 3 VALOR Trial in AML at ASCO 2011 Annual Meeting,2011-06-06 07:32:00-04:00,SNSS,positive
1161299.0,"Top Percentage Gainers and Losers as of 2pm 5/12/11 (DSCO, OXGN, QCOR, QTWW, SNSS, RPTP, VICL, ORBK, PNSN, SPMD, CLWR, DEXO, CCIH, TNGN, NQ, SYMX, BAC, INTC)",2011-05-12 14:05:00-04:00,SNSS,negative
1161300.0,Sunesis Announces Publication of Nonclinical Data Demonstrating Activity of Vosaroxin Alone and in Combination With Cytarabine in Patients' Acute Myeloid Leukemia Blasts (SNSS),2011-05-05 07:14:00-04:00,SNSS,negative
1161301.0,"Top Percentage Gainers and Losers as of 2 p.m. 4/11/2011(TSTY, FLO, GLBC, LVLT, AMMD, ENDP, EFII, IDIX, BAC, SNSS, AFFX, MCP, CYH, QUIK, THC, TDSC, WPRT, SCEI, IRE)",2011-04-11 14:12:00-04:00,SNSS,negative
1161302.0,"Morning Roundup: Top-5 and Bottom-5 Percentage Gainers (CBST, QCOR, SNSS, PPHM, EXPE, LEDS, MERU, PSEC, CREE, AIXG)",2011-04-05 09:20:00-04:00,SNSS,neutral
1161303.0,Sunesis Pharmaceuticals Reports Q4 Loss of $0.23 per share,2011-03-29 07:45:00-04:00,SNSS,neutral
1161304.0,Sunesis Pharmaceuticals Reports Q4 EPS of $(0.23) vs. $(0.10),2011-03-29 07:34:00-04:00,SNSS,neutral
1161305.0,Sunesis Announces 1-for-6 Reverse Stock Split  ,2011-02-14 13:09:00-05:00,SNSS,neutral
1161306.0,RBC Capital Ups SNSS To Outperform,2010-12-20 07:13:00-05:00,SNSS,neutral
1161307.0,"Adam Feuerstein Thinks Merger May Be In Works In Biotech (CTIC, SNSS)",2010-10-20 11:40:00-04:00,SNSS,neutral
1161308.0,"Benzinga’s Top Pre-Market Gainers (OSTE, FMBI, SNSS, HNSN, CPBY, ETRM)",2010-01-14 08:27:00-05:00,SNSS,positive
1161309.0,"Benzinga’s News Roundup (SEED, WSM, FPL, SNSS, ETRM, AIR, RXII)",2010-01-14 08:03:00-05:00,SNSS,neutral
1161310.0,"Benzinga’s Biggest Losers (HLCS, CYCC, SNSS, AMED, APKT) ",2009-12-16 12:01:00-05:00,SNSS,negative
1161311.0,"Benzinga’s Top Gainers (SNSS, CBK, AA, NCR, ERJ)",2009-12-11 10:50:00-05:00,SNSS,positive
